The strategic addition to the team reflects Onyx Health’s commitment to setting the stage for a transformative period in the medical education market, and further strengthening their foothold in the healthcare industry.
Evoke’s audience intelligence offering is an omnichannel-ready, future-proofed solution that utilizes data with unmatched precision and provides critical insights on patients, caregivers, healthcare professionals, and payors.
It’s summer 2023. By now, many of us have “emerged”, as they say. We are getting out and about and making up for the lost time of the past three years. And much of this progress is thanks to the COVID-19 vaccines and treatments from Pfizer, BioNTech, and Moderna, which played a major role in helping us put the pandemic in the rearview mirror.
In a less-than-shocking development, the top drugs of the launch class of 2021 were all for preventing or treating everyone’s least favorite virus.
Lessons from biopharmas taking a patient-first approach.
The agency speaks with strategists and innovation specialists who have been tracking metaverse developments in health care. Here are their hot takes on Apple’s promising, pricey, and unpredictable foray into the Internet of tomorrow.
A nationally representative survey of 2,001 employed adults in the United States released by the health insurance company Aflac found that many — one in four — simply skip regular checkups because they are feeling healthy. According to the survey, about half of adults have avoided at least one common health screening, including tests for certain diseases and other exams.
Generative AI is going to transform the way HCPs and patients seek information.
Bringing a drug to market is harder than ever, and manufacturers continue to navigate a complex road to get therapies to patients. On average, manufacturers spend more than $125 million over the three years leading up to launch, yet two-thirds of drugs fail to meet launch expectations.
Optimizing product launches has never been more challenging or more vital. The challenges of stiff competition, a shift toward more specialty drugs with smaller patient populations, restricted physician access, and the growing influence of payers, make it essential for launch teams to be as strategic and efficient as possible.
